OPEN END TURBO OPTIONSSCHEIN LONG - ASTRAZENECA | Real-time Bid/Ask 10:23:14 2024-06-13 am EDT | ||
| 0.88 EUR / 0.89 EUR | -11.50% |
|
| Current month | +66.67% | ||
| 1 month | +2.04% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ASTRAZENECA PLC
Latest news about ASTRAZENECA PLC
More news
| Date | Price | Change |
|---|---|---|
| 24-06-13 | 0.99 | -1.00% |
| 24-06-12 | 1 | -10.71% |
| 24-06-11 | 1.12 | -4.27% |
| 24-06-10 | 1.17 | +11.43% |
| 24-06-07 | 1.05 | -11.02% |
Delayed Quote Börse Stuttgart
Last update June 13, 2024 at 05:29 am EDT
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | ASTRAZENECA PLC |
| Issuer | Goldman Sachs |
| WKN | GG74AQ |
| ISIN | DE000GG74AQ0 |
| Date issued | 2024-04-26 |
| Strike | 11,634 p |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 0.64 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 1.18 € |
|---|---|
| Lowest since issue | 0.53 € |
| Spread | 0.01 € |
| Spread % | 1.11% |
Company Profile
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (4.4%).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Sector
-
Consensus: AstraZeneca PLC
Sell
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
160.1
USD
Average target price
174.4
USD
Spread / Average Target
+8.96%
- Stock Market
- Certificates
- Certificat
